Moreover, we identified a potential novel inhibitor, compound 513457, which disrupts CCND1-CDK4 interactions similarly to p21, offering a promising avenue for targeted therapy in NSCLC. This evidence concerns the gene CDKN1A and non-small cell lung carcinoma.